25 Sep 2012

NIB funds Getinge’s R&D in ventilation and anaesthesia

NIB has signed an 8-years maturity loan of USD 90 million with the Swedish medical equipment supplier Getinge AB. The loan will finance R&D to improve the usage of Getinge’s ventilation and anaesthesia products.

The R&D activities are aimed at improving the re-usability of components in different applications, helping customers integrate Getinge’s products to other hospital systems and reducing complexity. Improved automated monitoring and control of patients is also expected to improve productivity. The research and development project utilises skills and technologies developed by several Nordic technology companies and will take place in Solna, Sweden, by Getinge’s subsidiary Maquet Critical Care AB.

“The loan will further enhance Getinge’s competitiveness and the new knowledge created by its R&D is likely to benefit NIB’s other member countries,” says Henrik Normann, NIB President and CEO.

Getinge Group is a leading global provider of products and systems within healthcare and life sciences. It operates under the brands of ArjoHuntleigh, Getinge and Maquet. ArjoHuntleigh focuses on patient mobility and wound management solutions. Getinge provides solutions for infection control within healthcare and contamination prevention within life sciences. Maquet specialises in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care. Getinge is listed on the Nasdaq OMX Stockholm exchange.

NIB is a multilateral financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact
Mr Lars Synnes, Senior Manager, Origination, +358 50 562 3604,

Mr Arild Moen, Senior Communications Officer, +358 10 618 0496,